Humans are in a constant arms race with infectious bacteria. To kill these disease microbes, we develop powerful antibiotics; and in turn, the bacteria develop resistance against these drugs. So we enhance our antibiotics, and the bacteria enhance themselves accordingly—resulting in so-called superbugs. Increasingly, medications fail to eliminate these highly adapted bacteria, leaving our bodies dangerously defenseless.
In light of this crisis, for almost 20 years Rockefeller’s Vincent A. Fischetti has been developing a novel form of antimicrobial ammunition known as lysins. Now, these bacteria-killing enzymes have been studied in a phase II human clinical trial, becoming the first antibiotic alternatives to achieve successful outcomes in this stage of clinical development.
Natural born killer
Some viruses are very good at killing bacteria. Known as bacteriophages, or simply phages, these viruses infect a microbe, replicate inside of it, and then produce lysin enzymes, which cleave the bacterium’s cell wall. As a result, progeny phages are released from within the bacterium, and the bacterium itself perishes.
In nature, this kind of assault is commonplace: bacteriophages inhabit everything from oceans and soil to human bodies, helpfully regulating microbe populations wherever they go. In fact, every 48 hours half the bacteria on earth are killed by phages, making lysins the most widespread bacteria-killing agents on Earth.
In the lab, lysins can be used as a tool to break down and study the cell walls of bacteria—which is exactly what Fischetti was doing at Rockefeller about two decades ago. Simultaneously, his lab was also working on a vaccine for streptococcus infections, and the broader research community was becoming increasingly worried about antibiotic-resistant infections. This confluence of events led Fischetti to a breakthrough.
“Since I was working with lysins, I knew they killed bacteria instantly. My lab happened to have animals that were orally colonized with streptococci for my vaccine studies,” he recalls. “So, I thought, let me just give these colonized mice some lysin and see what happens to the streptococci.”
The effect was dramatic: an hour after getting the drug, the animals were decolonized of their streptococci. The subsequent publication of this finding was the first to report the therapeutic use of phage lysins.
Compelled by this result, Fischetti and later other scientists began developing lysins against several types of drug-resistant bacteria, many of which successfully cured infections in a wide range of animal models. Until recently, however, no one had tested whether this type of therapy was safe and effective in humans.
A new approach
Drug-resistant bacteria are especially dangerous—and especially common—in hospitals, where infection can complicate the outcomes of already-sick patients. Of particular concern in this setting is infection with methicillin-resistant Staphylococcus aureus (S. aureus), or MRSA. Though some cases of MRSA are mild, the bacterium can be life-threatening if it spreads to the blood, a condition known as bacteremia.
As the “methicillin-resistant” part of its name suggests, MRSA doesn’t respond to standard antibiotics—which makes it an ideal candidate for treatment with a new kind of bacteria killer. To this end, seven and a half years ago the biotechnology company ContraFect licensed from Rockefeller a lysin that targets Staphylococci, as well as some Streptococci. The company then developed the lysin, now called exebacase, for the treatment of human S. aureus infections, including MRSA.
Following a phase I clinical trial showing that exebacase did not lead to any serious side effects in humans, ContraFect advanced the research into a randomized, double-blind, placebo-controlled phase II study of hospitalized patients with S. aureus bacteremia, approximately one third of whom had MRSA. 116 of these patients were randomly assigned to receive either exebacase or placebo, in addition to antibiotic therapy, and were followed for fourteen days. The researchers found that the rate of treatment response was more than 40 percent higher for MRSA patients receiving exebacase than for those treated with antibiotics alone—a result Fischetti views as very encouraging not only for exebacase, but for lysins at large.
“This is the first time a lysin-based drug has gone this far in clinical development. In fact, there is no antibiotic alternative that has ever successfully completed phase II trials,” he says. “More work needs to be done, but this study is very promising.”
Moving forward, ContraFect intends to conduct a larger phase III trial, which is necessary for the lysin to be approved as a medicine.
Fischetti hopes that the development of exebacase is part of broader shift in how researchers and clinicians think about the management of bacterial infections. “Bacteria are growing more and more resistant to antibiotics,” he says. “And we’re showing that there are other ways to fight them.”
Newly engineered enzyme is a powerful staph antibiotic
Quick Take: Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all-cause mortality
Urinary tract infection (UTI) is the most common bacterial infection in elderly patients, and the spectrum of illness ranges from...
Quick Take: Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines
Antibiotic resistance is a growing challenge across the globe. As such, there have been increasing efforts towards reducing unnecessary or...
Quick Take: Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics
Systemic antibiotics are commonly used in the treatment of acne. However, the impact of their use on the complete bacterial...
New herpes zoster vaccine predicted to be more cost effective than predecessor
1. In a computational model, the new “recombinant zoster vaccine” (RZV) was predicted to be most cost-effective than the previous...
BIOLOGY2 weeks ago
The largest ever catalog of bacteria in the human body contain over 150 thousands genomes
LATEST NEWS4 weeks ago
Risk of red meat allergy from tick bites higher than previously thought
LATEST NEWS4 weeks ago
Researchers explore why common antibiotic prescribed for diarrhea is failing
LATEST NEWS3 weeks ago
Mother’s dengue immunity influences the severity of Zika infection in infants
LATEST NEWS3 weeks ago
How helpful gut microbes send signals that they are friends, not foes
LATEST NEWS1 week ago
Curing HIV just got more complicated. Can CRISPR help?
HEALTH4 weeks ago
What Are Parabens?
BIOLOGY2 weeks ago
Sewage reveals levels of antimicrobial resistance worldwide